HCPCS code J1700 – Hydrocortisone acetate injection

Key takeaways

J1700 covers hydrocortisone acetate injection only. Hydrocortisone sodium succinate bills under J1720, which uses a 100 mg unit.

One billing unit equals up to 25 mg administered, and any part-unit above a multiple of 25 mg rounds up to the next whole unit.

J1700 bills the drug only, so pair it with the administration code for the route, such as 20610 for a major joint.

Medicare Part B pays J1700 at ASP+6% in a physician office. In a hospital outpatient department, the drug is usually bundled into the facility payment.

Missing or invalid NDC data and J1720 billed in place of J1700 are two common, preventable causes of denial.

HCPCS code J1700: Definition and official descriptor

HCPCS code J1700 is defined by the Centers for Medicare and Medicaid Services (CMS) as “Injection, hydrocortisone acetate, up to 25 mg.” It belongs to the J-code series within HCPCS Level II, the code set CMS maintains for drugs, biologicals, and supplies not covered by CPT. You can compare it with neighboring drug codes in our HCPCS codes library.

The key clinical detail is the salt form: Hydrocortisone acetate. This formulation is a suspension rather than a solution, so it produces a slower, more localized effect. It is typically administered by intra-articular, intralesional, or soft-tissue injection for inflammatory conditions rather than by intravenous infusion for systemic emergencies.

Billing units and dosage calculation for J1700

One unit of J1700 equals up to 25 mg of hydrocortisone acetate administered. Bill based on the dose given to the patient, not the total volume in the vial. A vial may contain 50 mg, but if the clinician administers only 25 mg, the correct quantity is one unit.

Billing the vial volume instead of the administered dose is a frequent unit error on J1700 claims. Bill one unit for any dose up to 25 mg. When a dose exceeds a multiple of 25 mg, bill the next whole unit (e.g. 30 mg = 2 units). This follows Medicare Claims Processing Manual Chapter 17. Follow payer policy where it differs.

When billing multiple units, document each injection site separately in the administration record. Payers may audit unit counts against the documented clinical notes, so the administration record must show site, dose, and route for every unit claimed.

HCPCS code J1700 vs J1720: Key differences

J1700 covers hydrocortisone acetate, a suspension. J1720 covers hydrocortisone sodium succinate, a solution. The two salts have different clinical uses, so the salt named in the physician order decides the code.

The physician order and medication administration record must state the salt form explicitly. Billing staff cannot infer the correct code from the drug name alone if only “hydrocortisone” appears in the chart without the salt qualifier.

Related codes to know when billing hydrocortisone injections

J1700 rarely appears on a claim by itself. An administration code and a diagnosis code are always required, and certain situations call for J3490 as a fallback. The table below covers the codes most often billed alongside, or confused with, J1700.

The route in the administration record decides the administration code. Intra-articular injection bills with 20600–20611, chosen by joint size and ultrasound use, so a major joint without ultrasound is 20610. Intralesional injection bills with 11900 for up to 7 lesions, or 11901 for more.

Code 96372 applies only when J1700 is given subcutaneously or intramuscularly, which is uncommon for the acetate suspension. Check National Correct Coding Initiative (NCCI) edits for your payer before billing any administration code with J1700. Some contractors require a modifier to report both on one claim. The map below pairs each route with its code.

Medicare coverage and reimbursement for J1700

Medicare Part B covers J1700 when the drug is given incident to a physician’s service in a non-facility setting. The documented diagnosis must also support medical necessity. Payment is set at ASP+6% (average sales price plus 6%), effectively about ASP+4.3% after the 2% sequestration reduction. CMS updates the rate quarterly.

Because the rate moves every quarter, check the current payment limit in the CMS ASP drug pricing file before you estimate reimbursement.

Place of service and drug bundling

Place of service (POS) determines whether a separate J-code claim for J1700 is appropriate at all.

• POS 11 (physician office): The drug is billed separately using J1700 alongside the administration and E&M codes. This is the non-facility setting where ASP+6% applies.
• POS 22 (hospital outpatient department): The drug cost is generally bundled into the facility’s Ambulatory Payment Classification (APC) payment. That payment falls under the Outpatient Prospective Payment System (OPPS). The physician does not separately bill J1700 in this setting.
• POS 24 (ambulatory surgical center): Drug costs are typically included in the ASC payment package. Separate J-code billing by the physician is generally not appropriate.

Where the drug is already bundled into the facility’s claim, a separate J1700 bill is an overpayment risk and a common audit trigger. Verify with your MAC and the facility’s billing department before submitting a separate drug claim in any setting other than the physician office.

Prior authorization requirements for J1700

Prior authorization (PA) requirements for J1700 vary by payer, plan year, and state Medicaid program. Traditional Medicare Part B does not universally require prior authorization for J1700. Medicare Advantage plans and most commercial payers may impose their own PA criteria. Always verify with the specific plan before administering the drug if any question of coverage exists.

When PA is required, the supporting documentation typically includes:

• Documented diagnosis with ICD-10-CM code establishing medical necessity
• Treatment history showing prior conservative management (e.g. physical therapy, oral anti-inflammatories) where the payer requires step therapy
• Prescriber attestation confirming the clinical indication for the hydrocortisone acetate injection
• Dose and route documented in the physician order

For Medicaid, PA requirements differ by state. Some state Medicaid programs restrict corticosteroid injections to specific diagnoses or require physician specialty attestation. Confirm requirements with your state Medicaid agency or managed care organization before billing.

Required documentation for J1700 claims

Every J1700 claim must be supported by the following records, all in the patient’s medical chart:

• Physician order: Must specify hydrocortisone acetate by name and salt form, dose in mg, route, and site of administration
• Administration record: Date, time, dose administered, route, site, and name of the administering clinician
• NDC number: The National Drug Code for the product used, plus the NDC qualifier (UN for units, ML for milliliters, GR for grams) and quantity. Medicaid claims and many Medicare contractors require it.
• ICD-10-CM diagnosis code: Must reflect the specific clinical indication documented in the chart. Avoid an “unspecified” code where a more specific one is available.
• Place-of-service code: Must accurately reflect where the injection was administered
• Prescriber NPI: The ordering and billing provider’s National Provider Identifier

The superbill documentation generated at the point of care should capture each of these fields before the claim is submitted. A claim built from an incomplete superbill is hard to defend when an auditor or payer reviewer asks for the record.

ICD-10-CM diagnosis codes that support J1700

The ICD-10-CM diagnosis code on a J1700 claim must reflect the specific condition for which the hydrocortisone acetate injection was clinically indicated. Common diagnoses paired with J1700 include inflammatory joint conditions, soft-tissue inflammation, and certain dermatological indications.

Always select the most specific ICD-10-CM code available for the documented diagnosis. Generic codes like M79.3 (panniculitis, unspecified) should only be used when the chart does not support a more specific code. Payers may deny claims coded to “unspecified” when a specific code clearly applies.

Common denial reasons for J1700 claims

J1700 denials usually trace back to a coding or documentation slip that can be caught before submission. The six patterns below pair each common denial with its root cause and fix, drawn from standard denial management practice.

How Pabau supports accurate J1700 billing

The denials above start at the point of care, when the salt, dose and route are written down, and surface weeks later on the claim. Pabau, the practice management and billing platform we build, keeps both ends in one place with its claims management software.

Many practices still bill injection drugs like J1700 from free-text notes. The billing team has to find the salt form, dose, NDC, route and site in the chart before the claim can go out. Each manual lookup is a chance to bill J1720 by mistake or miscount units.

• One patient record: The treatment note, the invoice and the claim sit in the same system, so nobody re-keys injection details between tools.
• Claims raised from the invoice: Each claim opens pre-filled from the patient’s invoice, ready to validate and send to your clearinghouse.
• Claim validation: Pabau checks every claim for missing or invalid details before it leaves the system. A blank field gets fixed before the payer sees it.
• Rejection follow-up: A rejected claim is flagged as needing action, with a link straight to the field to correct. You fix it and resubmit in one place.

Insurance claiming is included in every Pabau subscription. Build your note templates around clean claim submission standards, and fewer J1700 claims come back for rework.

Manage J1700 billing from treatment note to claim

Pabau raises each claim from the patient’s invoice and validates it before submission. Hydrocortisone acetate billing errors get fixed before they reach the payer.

Book a demo

Conclusion

J1700 claims succeed or fail on details written at the point of care. Get the salt form, the administered dose and the route into the order and the administration record, and the right codes follow.

Your next step is a short audit of your last few J1700 claims. Check that each one bills J1700 rather than J1720, rounds units up from the dose given, and carries an administration code that matches the route. Any mismatch points to the note template or workflow to fix first.

The trade-off is a few extra fields per injection note in exchange for fewer denials and easier audits. Book a demo to see how Pabau carries injection details from the treatment note to a validated J1700 claim.

Continue your research

Need to understand how denials get resolved? Denial management in healthcare covers the full workflow from denial receipt through appeal, with common CARC code patterns.

Want to see how clean claims reduce write-offs? Clean claim submission explains every element a claim must pass before a payer processes it for payment.

Looking for a broader billing compliance framework? Medical billing compliance outlines the documentation, audit, and payer policy requirements that apply across drug injection billing.

Billing a different hydrocortisone salt? HCPCS code J1710 covers hydrocortisone sodium phosphate injection, with its own unit size and billing rules.

Injecting a major joint under ultrasound? CPT code 20611 explains the administration code for an ultrasound-guided major joint injection.

Frequently asked questions